Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity
Cell Reports · 2025-10 · 44 (10) · 116433
DOI: 10.1016/j.celrep.2025.116433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025-10. Verfasst von Wenjing Song und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospit…. Hauptthemen laut MEDLINE: Poly (ADP-Ribose) Polymerase-1, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Zhongnan Hospital of Wuhan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer immunotherapies are widely used to treat various cancers but are largely ineffective against pancreatic ductal adenocarcinoma (PDAC), with the underlying mechanisms poorly understood. UFMylation, a ubiquitin-like modification, regulates diverse biological and pathological processes, yet its role in PDAC remains unclear. This study reports that UFMylation drives PDAC growth and resistance to cancer immunotherapy. Mechanistically, the E3 ligase UFL1 facilitates PARP1 UFMylation, preventing its ubiquitination and degradation. Stabilized PARP1 enhances DNA damage repair, suppresses R-loop formation, and inhibits cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon gene (STING) activation, thereby promoting tumor immune evasion. In contrast, inhibiting UFMylation reverses these effects, facilitating tumor infiltration of cytotoxic CD8+ T cells and improving the efficacy of anti-PD-1 immunotherapy in the pancreatic tumor model. Clinically, UFL1 protein levels are positively correlated with PARP1 and inversely correlated with cGAS-STING activation and CD8+ T cell infiltration in PDAC. These findings highlight UFMylation as a promising therapeutic target to enhance immunotherapy in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Clinica…
- Department of Hepatobiliary and Pancreatic Surgery, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; State K…
- Department of Dermatology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.
Förderung
- Fundamental Research Funds for the Central Universities
- Zhongnan Hospital of Wuhan University
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- China Postdoctoral Science Foundation
Zitieren
APA
Song, W., He, C., Xing, X., Xu, G., Yao, Y., Li, H., Sun, Y., Xiong, W., Shi, Y., Tayier, D., Yu, K., Zhang, X., Xie, Z., Yuan, Y., Yang, Z., & Zhang, J. (2025). Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. Cell Reports, 44(10), 116433. https://doi.org/10.1016/j.celrep.2025.116433
Vancouver
Song W, He C, Xing X, Xu G, Yao Y, Li H, et al. Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. Cell Reports. 2025;44(10):116433. doi:10.1016/j.celrep.2025.116433
BibTeX
@article{Song2025,
author = {Song, Wenjing and He, Chuan and Xing, Xixin and Xu, Gaoshan and Yao, Yingmeng and Li, Haiou and Sun, Yishuang and Xiong, Wenjun and Shi, Yang and Tayier, Dilinigeer and Yu, Kechun and Zhang, Xue and Xie, Zuosong and Yuan, Yufeng and Yang, Zhiyong and Zhang, Jinfang},
title = {Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity},
journal = {Cell Reports},
year = {2025},
volume = {44},
number = {10},
pages = {116433},
doi = {10.1016/j.celrep.2025.116433}
}
EUVIMED